Testing effectiveness (Phase 2)Ended earlyNCT02340156
What this trial is testing
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Who this might be right for
RECURRENT GLIOBLASTOMA
SynerGene Therapeutics, Inc. 1